10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Swiss pharma giant Roche edged 1.02% higher to 252.15 Swiss francs this morning, after it was revealed it is seeking a position in the hot area of liver disease. 28 November 2018
New York-based cell and gene therapy specialist Axovant Sciences has agreed a new strategic partnership with Yposkesi, a Contract Development & Manufacturing Organization (CDMO) specializing in gene therapy vector manufacturing. 28 November 2018
The first children in the UK to receive a game-changing personalized therapy for cancer will start treatment at Great Ormond Street Hospital in London this week, NHS England announced yesterday. 28 November 2018
Canada-based Zymeworks and China’s BeiGene have entered into a strategic collaboration for the clinical development and commercialization of Zymeworks’ investigational ZW25 and ZW49 HER2-targeted bispecific antibodies. 27 November 2018
Shares in New York-based drugmaker Bristol-Myers Squibb are faring poorly in pre-market trading, after the firm announced a Phase III trial flop for its combination Opdivo (nivolumab) plus Yervoy (ipilimumab) therapy. 27 November 2018
Israel and USA-based biotech Anchiano Therapeutics today announced the appointment of David Kerstein, as the company’s new chief medical officer (CMO). 27 November 2018
The Ireland Strategic Investment Fund (ISIF), an Irish sovereign development fund, WuXi NextCODE, the emerging global standard platform for genomics, and Irish life sciences company Genomics Medicine Ireland (GMI), today announce details of a $400 million investment program aimed at making Ireland an important hub for genomics research and development of new disease treatments and cures. 27 November 2018
US biotech suffered another setback in drug development yesterday, as the US regulator put a clinical hold on its investigational drug ZGN-1061. 27 November 2018
Switzerland’s Roivant Sciences has launched a new biotech startup, in collaboration with the Cincinnati Children's Hospital Medical Center, called Aruvant Sciences. 27 November 2018
Just over 140 years ago, the world’s first industrial-sized research and development laboratory opened. As someone who’s devoted his working life to finding new research and development (R&D) breakthroughs, I’m envious of the explosion of activity that made the lab’s owner, Thomas Edison, one of history’s most remarkable inventors. But it’s his process of innovation that inspires me, as much as his life-changing creations. 27 November 2018
Greg MacMichael, the former global head of cell and gene therapy technical development and manufacturing at Swiss pharma giant Novartis, is one of five new recruits to join Axovant Sciences. 26 November 2018
It’s been a busy year for Promore Pharma (Nasdaq: PROMO), a Swedish developer of therapeutic peptides, which has made good progress in its two clinical assets, making the investment case more attractive to investors, noted Klas Palin, analyst at Sweden’s Redeye Equity Research. 26 November 2018
The European Commission has granted a marketing authorization to Poteligeo (mogamulizumab), a humanized monoclonal antibody (MAb) directed against CC chemokine receptor 4 (CCR4), for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. 26 November 2018
The European Court of Justice will not stand in the way of Roche’s cancer drug Avastin (bevacizumab) being prescribed for an unlicensed indication. 23 November 2018
In recent decades, the pharmaceutical industry has developed next-generation treatments for cystic fibrosis (CF) that have a real impact on patients’ lives and extend life expectancy considerably. 23 November 2018
Switzerland-based Novartis has won European approval for the one-time gene therapy Luxturna (voretigene neparvovec). The treatment was approved in the USA in late December 2017. 23 November 2018
The UK government-backed Cell and Gene Therapy Catapult (CGT Catapult) has launched a new apprenticeship program aimed at supporting the development of Advanced Therapy Medicinal Products (ATMP). 23 November 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024